– USA, MA – Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy platform to deliver novel immunotherapeutic payloads to solid tumors, announced the appointment of Andrew Hirsch to its Board of Directors.
About Andrew Hirsch
Since 2020, Andrew Hirsch has been President, CEO, and a member of the Board of Directors of C4 Therapeutics, a clinical-stage company advancing a pipeline of targeted protein degraders for a number of indications, including oncology. He was previously CFO and Head of Corporate Development at Agios Pharmaceuticals, President and CEO of BIND Therapeutics, CFO at Avila Therapeutics, and VP of Corporate Strategy and M&A at Biogen.
Akamis Bio also serves on the Board of Directors at Editas Medicine, where he is Chair of the Audit Committee.
About Akamis Bio
Akamis Bio is currently enrolling the Phase 1b FORTRESS study (NCT06459869) for its lead candidate, NG-350A, in individuals with locally advanced rectal cancer (LARC). The study is an open-label, single-arm, and multicenter trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with LARC and at least one risk factor for local or distant recurrence or with oligometastatic disease. The FORTRESS study builds upon the Akamis Bio-supported, CEDAR study, which showed a significantly greater complete response rate in LARC patients treated with a combination of Akamis Bio’s first-generation immunotherapy and chemoradiotherapy (CRT), relative to expected outcomes using standard-of-care CRT alone. NG-350A is an intravenously delivered T-SIGN therapeutic designed to drive intratumoral expression of a CD40 agonist monoclonal antibody, triggering the activation of antigen-presenting cells (APCs) resident in solid tumors and their draining lymph nodes. Once activated, APCs recruit T cells into the vicinity of the tumor to deliver a potent anti-tumor immune response. Prior clinical studies of NG-350A have demonstrated a favorable safety profile for the therapy, with no observed transgene-related or off-target toxicities.
Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered immunotherapies to treat solid tumors, initially in patients with locally advanced rectal cancer. Its proprietary Tumor-Specific Immuno-Gene Therapy platform is designed to deliver novel immunotherapeutic proteins, biomolecules, and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody.
For more information: https://www.akamisbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.